164 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
NVO Novo Nordisk A/S $47.64 $114.84B N/A
Article Searches
AstraZeneca's Bydureon Fails to Reduce Cardiovascular Risk http://www.zacks.com/stock/news/261771/astrazenecas-bydureon-fails-to-reduce-cardiovascular-risk?cid=CS-ZC-FT-261771 May 24, 2017 - AstraZeneca plc (AZN) announced top-line results from the EXSCEL study evaluating the cardiovascular (CV) safety profile of its type II diabetes drug Bydureon.
3 Beaten-Up Healthcare Stocks: Are They Bargains? https://www.fool.com/investing/2017/04/19/3-beaten-up-healthcare-stocks-are-they-bargains.aspx?source=iedfolrf0000001 Apr 19, 2017 - The past year hasn't been kind to shareholders of Alexion Pharmaceuticals, Opko Health, and Novo Nordisk. Do their stocks hold value today, or should they be avoided?
High-Yield Healthcare Investments You Can Buy Right Now https://www.fool.com/investing/2017/04/18/high-yield-healthcare-investments-you-can-buy-righ.aspx?source=iedfolrf0000001 Apr 18, 2017 - Want high dividend yields? Check out healthcare stocks AbbVie, Pfizer, and Novo Nordisk.
Merck's Bid to Add Cardiovascular Data on Januvia Label Fails http://www.zacks.com/stock/news/255888/mercks-bid-to-add-cardiovascular-data-on-januvia-label-fails?cid=CS-ZC-FT-255888 Apr 10, 2017 - Merck announced that the FDA has denied approval to include cardiovascular outcomes data on the labels of its diabetes drug, Januvia (sitagliptin) and other medicines containing Januvia.
Novo Nordisk: Positive CHMP Nod for Tresiba Label Expansion http://www.zacks.com/stock/news/254428/novo-nordisk-positive-chmp-nod-for-tresiba-label-expansion?cid=CS-ZC-FT-254428 Mar 28, 2017 - Novo Nordisk A/S (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP), has issued a positive opinion suggesting an update to the label for Tresiba (insulin degludec) to include data from the SWITCH studies.
Orexigen Inks Commercialization Deal for Contrave, Stock Up http://www.zacks.com/stock/news/254403/orexigen-inks-commercialization-deal-for-contrave-stock-up?cid=CS-ZC-FT-254403 Mar 28, 2017 - Orexigen Therapeutics, Inc.'s (OREX) announced that it has entered into a commercialization and distributorship agreement with Italian pharmaceutical company, Bruno Farmaceutici, for its obesity drug, Contrave.
Novo Nordisk's Diabetes Unit Strong; Generic Pressure Stays http://www.zacks.com/stock/news/252549/novo-nordisks-diabetes-unit-strong-generic-pressure-stays?cid=CS-ZC-FT-252549 Mar 13, 2017 - We issued an updated research report on Novo Nordisk (NVO) on Mar 9, 2017.
Merck/Pfizer's Diabetes Drug Accepted for Review by FDA, EMA http://www.zacks.com/stock/news/252113/merck-pfizers-diabetes-drug-accepted-for-review-by-fda-ema?cid=CS-ZC-FT-252113 Mar 08, 2017 - Merck & Co., Inc. (MRK) and partner Pfizer, Inc. (PFE) announced that the FDA has accepted its new drug applications (NDA) for ertugliflozin as a monotherapy as well as two fixed-dose combination tablets.
Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International http://www.zacks.com/stock/news/251359/zacks-industry-outlook-highlights-sanofi-astrazeneca-novo-nordisk-gilead-sciences-and-valeant-pharmaceuticals-international?cid=CS-ZC-FT-251359 Mar 02, 2017 - Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International
Pricing to Remain Pharma Headline Risk in 2017 http://www.zacks.com/commentary/105146/pricing-to-remain-pharma-headline-risk-in-2017?cid=CS-ZC--105146 Mar 01, 2017 - Pricing to Remain Pharma Headline Risk in 2017

Pages: 1...1011121314151617

<<<Page 15>